GSK Acquires Nuvalent for $10.6 Billion in Major Lung Cancer Push

Dr. Rachel Mendez MD, Medical Science Writer

✨ Why this is good news

Non-small cell lung cancer is a common form of lung cancer that can be driven by specific genetic mutations.

Two new targeted drugs.GSK acquired zidesamtinib and NVL-330, two late-stage therapies for specific genetic subtypes of non-small cell lung cancer. Before this, patients with these mutations had limited treatment options, but now two new drugs are closer to reaching them.
FDA decisions expected soon.Both drugs are under FDA review with decisions due later this year, meaning patients may not have to wait years for access. This accelerates the timeline for those with ROS1-positive and HER2-mutant lung cancers.
Expanded treatment for rare mutations.Zidesamtinib targets ROS1-positive NSCLC, a rare but aggressive form of lung cancer. Previously, few therapies addressed this specific mutation, so this drug offers a new precision option for a group that was underserved.
GSK’s major lung cancer commitment.The $10.6 billion acquisition marks a strategic shift from GSK’s focus on gynecological and blood cancers to lung cancer. This investment signals that more resources and research will now be directed toward improving outcomes for NSCLC patients.

GSK is making a bold bet on lung cancer, announcing a $10.6 billion deal to acquire Nuvalent and its two late-stage targeted therapies. The acquisition signals a strategic shift for the pharmaceutical company, which has traditionally focused on gynecological and blood cancers but now aims to become a major player in non-small cell lung cancer (NSCLC). Both drugs are currently under review by the U.S. Food and Drug Administration, with decisions expected later this year.

The first drug, zidesamtinib, targets ROS1-positive NSCLC, a form of lung cancer driven by a specific genetic mutation. It is designed to overcome limitations of existing ROS1 inhibitors, including drug resistance and the spread of cancer to the brain. The FDA is expected to rule on zidesamtinib as a second-line treatment by September 18, with ongoing studies potentially supporting a first-line indication. The second drug, neladalkib, targets ALK-positive NSCLC, a more common subtype. It is designed to remain effective in tumors that have become resistant to earlier ALK inhibitors and to penetrate the brain to treat metastases. The FDA has set a November 27 target date for a decision on neladalkib.

A Broader Oncology Ambition

The Nuvalent acquisition is not GSK’s only move in lung cancer. The company also holds global rights to risuvatug-rezetecan, an antibody-drug conjugate from Hansoh Pharma that is currently in Phase 3 testing for extensive-stage small cell lung cancer. In addition, GSK recently acquired IDRx for $1 billion, adding a Phase 3 drug for gastrointestinal stromal tumors to its pipeline. These deals reflect a broader strategy to build a diversified oncology portfolio around proven biological targets with clear unmet medical needs.

GSK CEO Luke Miels said the Nuvalent drugs could be “potential best-in-class assets” that may launch this year if approved. The company’s oncology division currently generates about $2.63 billion in annual revenue, a figure that could grow significantly with the addition of these lung cancer therapies. GSK is paying $124 per share for Nuvalent, a 40 percent premium over the biotech’s recent stock price, with a net cash-adjusted outlay of approximately $9.4 billion.

If the FDA approves both drugs by their respective deadlines, GSK could enter the lung cancer market with two novel oral therapies by the end of 2025. For patients with ROS1- or ALK-driven NSCLC who have limited options after standard treatments fail, these drugs may offer new hope for durable responses and better quality of life.

This article is for informational purposes only and does not constitute medical advice. The information presented is based on published research and official announcements. Always consult a qualified healthcare professional before making any medical decisions.